HRP20080330T3 - Antitumoral compounds based on kahalalide f - Google Patents

Antitumoral compounds based on kahalalide f

Info

Publication number
HRP20080330T3
HRP20080330T3 HR20080330T HRP20080330T HRP20080330T3 HR P20080330 T3 HRP20080330 T3 HR P20080330T3 HR 20080330 T HR20080330 T HR 20080330T HR P20080330 T HRP20080330 T HR P20080330T HR P20080330 T3 HRP20080330 T3 HR P20080330T3
Authority
HR
Croatia
Prior art keywords
kahalalide
compounds based
antitumoral compounds
antitumoral
new analogues
Prior art date
Application number
HR20080330T
Other languages
English (en)
Croatian (hr)
Inventor
Albericio Palomera Fernando
Fernandez Donis Ariadna
Giralt Lledo Ernest
Gracia Cantador Carolina
Lopez Rodriguez Pilar
Varon Colomer Sonia
Cuevas Marchante Carmen
Lopez Macia Angel
Francesch Solloso Andr�s
Jiminez Garcia Jos�-Carlos
Royo Exposito Miriam
Original Assignee
Pharma Mar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar filed Critical Pharma Mar
Publication of HRP20080330T3 publication Critical patent/HRP20080330T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20080330T 2003-09-09 2008-07-07 Antitumoral compounds based on kahalalide f HRP20080330T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321066.3A GB0321066D0 (en) 2003-09-09 2003-09-09 New antitumoral compounds
PCT/GB2004/003847 WO2005023846A1 (en) 2003-09-09 2004-09-09 New antitumoral compounds

Publications (1)

Publication Number Publication Date
HRP20080330T3 true HRP20080330T3 (en) 2009-04-30

Family

ID=29226738

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080330T HRP20080330T3 (en) 2003-09-09 2008-07-07 Antitumoral compounds based on kahalalide f

Country Status (23)

Country Link
US (1) US20070117743A1 (de)
EP (6) EP1664093B8 (de)
JP (4) JP4874796B2 (de)
KR (1) KR20060073618A (de)
CN (2) CN100467482C (de)
AT (1) ATE393776T1 (de)
AU (2) AU2004270471B2 (de)
CA (1) CA2537128A1 (de)
CY (1) CY1108226T1 (de)
DE (1) DE602004013454T2 (de)
DK (2) DK1664093T3 (de)
ES (2) ES2536285T3 (de)
GB (1) GB0321066D0 (de)
HR (1) HRP20080330T3 (de)
HU (1) HUE025308T2 (de)
IL (1) IL173929A (de)
MX (1) MXPA06002741A (de)
NZ (4) NZ580124A (de)
PL (1) PL1664093T3 (de)
PT (1) PT1664093E (de)
RU (2) RU2395520C2 (de)
SI (1) SI1664093T1 (de)
WO (1) WO2005023846A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
RU2010119922A (ru) * 2007-10-19 2011-11-27 Фарма Мар, С.А. (Es) Усовершенствованное противоопухолевое лечение
WO2009095480A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
EP2262522A1 (de) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Verbesserte antitumorale behandlungen
CN101519437B (zh) * 2009-04-09 2012-05-02 中国人民解放军第二军医大学 西沙海绵中一种环七肽类化合物及其用途
CN104725266B (zh) * 2014-04-10 2016-08-10 申俊 酰亚胺类化合物的合成方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ID19609A (id) * 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
SK286421B6 (sk) 2000-10-31 2008-09-05 Pharma Mar, S. A. Prostriedok kahalalid F, súprava, rekonštituovanýa zriedený roztok s obsahom tohto prostriedku a použitie
EP1435990A1 (de) 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalid-verbindungen zur verwendung in der krebstherapie
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
BR0315489A (pt) 2002-10-18 2005-08-23 Pharma Mar Sau Composição antitumorais
KR20110114690A (ko) * 2002-10-18 2011-10-19 파르마 마르 에스.에이.유. 4-메틸헥사노 카할라리드 f 화합물
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds

Also Published As

Publication number Publication date
JP4874796B2 (ja) 2012-02-15
AU2004270471A1 (en) 2005-03-17
ATE393776T1 (de) 2008-05-15
EP1664093B1 (de) 2008-04-30
EP2280026A3 (de) 2011-05-25
EP1664093A1 (de) 2006-06-07
RU2009147217A (ru) 2011-06-27
DE602004013454D1 (de) 2008-06-12
JP2012051899A (ja) 2012-03-15
EP1918296B1 (de) 2012-11-14
CN1849333A (zh) 2006-10-18
CY1108226T1 (el) 2014-02-12
EP2664623B1 (de) 2015-03-04
IL173929A0 (en) 2006-07-05
EP1918296A3 (de) 2009-06-24
NZ580124A (en) 2011-01-28
NZ595490A (en) 2013-04-26
EP1664093B8 (de) 2008-08-13
PL1664093T3 (pl) 2008-10-31
IL173929A (en) 2014-01-30
MXPA06002741A (es) 2006-06-05
NZ545700A (en) 2010-03-26
NZ589890A (en) 2011-11-25
CN101531707A (zh) 2009-09-16
ES2536285T3 (es) 2015-05-22
SI1664093T1 (sl) 2008-12-31
WO2005023846A1 (en) 2005-03-17
EP2280025A2 (de) 2011-02-02
EP2280025A3 (de) 2011-05-25
CA2537128A1 (en) 2005-03-17
JP5372096B2 (ja) 2013-12-18
JP2012031188A (ja) 2012-02-16
GB0321066D0 (en) 2003-10-08
EP2280027A3 (de) 2011-05-04
HUE025308T2 (en) 2016-01-28
EP1918296A2 (de) 2008-05-07
EP2664623A1 (de) 2013-11-20
DE602004013454T2 (de) 2009-06-18
AU2004270471B2 (en) 2011-06-02
EP2280026A2 (de) 2011-02-02
JP2012031187A (ja) 2012-02-16
DK1664093T3 (da) 2008-08-18
PT1664093E (pt) 2008-08-07
AU2011202286A1 (en) 2011-06-09
AU2011202286B2 (en) 2013-08-01
DK2664623T3 (en) 2015-05-11
KR20060073618A (ko) 2006-06-28
RU2006111491A (ru) 2007-11-20
ES2305843T3 (es) 2008-11-01
CN100467482C (zh) 2009-03-11
JP2007526904A (ja) 2007-09-20
EP2280027A2 (de) 2011-02-02
RU2395520C2 (ru) 2010-07-27
US20070117743A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
HRP20080330T3 (en) Antitumoral compounds based on kahalalide f
SG145694A1 (en) Novel compounds
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
AU2003219916A8 (en) Bioengineered tissue substitutes
EP1509725A4 (de) Lichtquellenanordnung
IL176328A0 (en) Method for purifying fsh
PT1562941E (pt) Trans-9,10-desidroepotilona c e d, seus análogos e métodos de fabrico dos mesmos
HU0200183D0 (en) Carbon dioxide blown low density, flexible microcellular elastomers suitable for preparing shoe component
HK1065786A1 (en) Antitumoral analogs
AU2003259494A8 (en) Current source for cryptographic processor
TW200510398A (en) Novel compounds
GB0211161D0 (en) Millimetre-wave illumination source
EP1592040A4 (de) Elektronenquelle
SG147408A1 (en) Additive mixtures
PT1492501E (pt) Métodos de uso de corpos lamelares para propósitos terapêuticos
SG148154A1 (en) Benzannelated compounds as ppar activators
AU2003249999A8 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
AU148415S (en) Bottle
GB0206811D0 (en) Source mixture
GB0215630D0 (en) New antitumoral compounds
GB0328335D0 (en) High brightness electron source
MD2731B2 (de)
GB0314304D0 (en) Antitumoral compounds
GB0318336D0 (en) Antitumoral compounds
GB0314724D0 (en) Antitumoral compounds